Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis

INTRODUCTION: Rheumatoid arthritis (RA) is a chronic autoimmune disease requiring long-term treatment. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor, is a new treatment for RA. The benefit–risk profile of a medication is best understood by evaluating the number needed to treat (NNT) and the num...

Descripción completa

Detalles Bibliográficos
Autores principales: Conaghan, Philip, Cohen, Stanley, Burmester, Gerd, Mysler, Eduardo, Nash, Peter, Tanaka, Yoshiya, Rigby, William, Patel, Jayeshkumar, Shaw, Tim, Betts, Keith A., Patel, Pankaj, Liu, Jianzhong, Sun, Rochelle, Fleischmann, Roy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814262/
https://www.ncbi.nlm.nih.gov/pubmed/34816388
http://dx.doi.org/10.1007/s40744-021-00399-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814262/
https://www.ncbi.nlm.nih.gov/pubmed/34816388
http://dx.doi.org/10.1007/s40744-021-00399-5

Ejemplares similares